The tape is nine weeks deep and starting to sweat

The tape is nine weeks deep and starting to sweat

Short week, big moves. The S&P 500 jumped to 7,580, up 1.4%, and logged nine straight winning weeks. The Nasdaq 100 punched through 30,000 and settled at 30,333, up 2.9% — even as its trend is shaping into a bearish rising wedge with momentum visibly slowing. Weekly RSI for the S&P is at its highest reading in nearly two years. That's usually the part where traders stop smiling and start quietly checking the exits.

Gobble's Take: Nine straight winning weeks sounds great until you remember that staircases have landings. Source: KBL_Destinations_Trading_LLC

Dell just had the best day of its entire life

Dell gapped up 33% after crushing earnings expectations — its best single-day performance ever. That lands it among the most volatile names in the S&P 500, and it's easy to see why: the company reported an AI order backlog of $51.3B. This wasn't a tidy little beat. It was a full-volume, broad-daylight re-pricing.

Gobble's Take: When a stock doubles in two months and still looks hungry, the chart stops being polite. Source: KBL_Destinations_Trading_LLC

Gold is holding its line and making it look easy

Gold is trading around 4,565, showing a strong bullish impulse right off the 200-day moving average — a level that has already acted as reliable support twice before. The broader trend stays intact as long as that floor holds. One wrinkle: the daily chart is flashing bearish RSI divergence, even as the weekly shows none of the warning signs that preceded past drawdowns.

Gobble's Take: Gold looks sturdy — but sturdy things still wobble when they've already sprinted a very long way. Source: DiviStock Chronicles

Cingulate ($CING) has an FDA decision pending for CTx-1301

Cingulate ($CING) is a catalyst-driven setup centered on the upcoming FDA decision for CTx-1301, its lead ADHD candidate. In October 2025, the FDA accepted for review the New Drug Application (NDA) for CTx-1301 and assigned a PDUFA target action date of May 31, 2026. NDA acceptance does not imply approval or guarantee any specific outcome.

The options market is treating this less like a routine regulatory checkpoint and more like a potential re-rating catalyst. The at-the-money straddle implies roughly a 50% move, with upside strikes pricing scenarios exceeding 100% gains into expiration. Bulls see commercial differentiation; bears point to competitive and execution risk.

Gobble's Take: The PDUFA date is May 31, 2026. The FDA decision will likely determine how investors value Cingulate going forward.

Source: Bowtied Biotech

In Case You Missed It

Yesterday's top stories:

• Futures open firm, oil spikes, and the chip sector stages a very public argument
• Snowflake is up 36% today and the chart is starting to look like a cry for help
• The rally is nearly at target, a sell signal is incoming, and the chart is not done yet